TUCSON, Ariz., August 6, 2024 — Critical Path Institute’s (C-Path) Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortium today announced the addition of several key advisory members. Continue reading
Author Archive: Roxan Olivas
C-Path’s Alzheimer’s Consortium Unveils Seminal Methodology to Enhance Alzheimer’s Clinical Trials Using Imaging Biomarkers
TUCSON, Ariz., July 26, 2024 – Critical Path Institute (C-Path) is proud to announce the publication of a new study in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association that was led by its Critical Path for Alzheimer’s Disease (CPAD) consortium. The publication details a method that solves a major obstacle to comparing the findings of investigational tau imaging results across Alzheimer’s disease (AD) clinical trials. Continue reading
C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with New Friedreich’s Ataxia Data
The team also announced the closure of the FA-ICD portal. Continue reading
C-Path’s Parkinson’s Consortium Supports Groundbreaking Research Utilizing Smartwatches to Monitor Disease Progression
TUCSON, Ariz., June 12, 2024 — Critical Path Institute (C-Path) today announced a new publication on how the use of wearable technology can optimize measuring symptoms important to people with Parkinson’s disease. The newly published manuscript in npj Parkinson’s Disease highlights a multistakeholder initiative consisting of collaborators from around the world coming together to share knowledge, data and resources to ask how new technologies can help to monitor people living with Parkinson’s in new ways.
C-Path’s AI Collaborations Accelerate Drug Development, Improve Lives
TUCSON, Ariz., June 12, 2024 — Critical Path Institute (C-Path) today announced the publication of a new peer-reviewed paper in the journal Clinical and Translational Science. As the preeminent leader in public-private partnerships to accelerate drug development, the paper highlights how C-Path’s AI collaborations are revolutionizing drug development, with specific advancements in the management and treatment of Type 1 Diabetes (T1D) and Parkinson’s Disease (PD). This study affirms the Institute’s commitment to using artificial intelligence (AI) and digital health technologies (DHTs) to expedite the delivery of life-saving treatments.
C-Path’s TRxA Announces its First Biologics-focused RFP for Academic Investigators
NEW FUNDING OPPORTUNITY!
C-Path’s International Neonatal Consortium and the National Association of Neonatal Nurses Open Access to Neonatal Drug Development Education Modules
The modules will help educate neonatal healthcare professionals in neonatal drug development, pipeline decision-making and addressing neonate needs in the current environment. Continue reading
From Diagnosis to Advocacy: Layne Oliff’s Unwavering Commitment to ALS Awareness and Action
By Alexander Diegel
Layne Oliff was an active runner who successfully completed 10-mile trail runs up until his 60th birthday — before he was diagnosed with amyotrophic lateral sclerosis (ALS) in November of 2020. Layne soon pivoted that same drive and commitment to another journey, as an active advocate in the ALS community.Continue reading
C-Path Appoints Dr. Amanda Klein as Executive Director for CPLD and CPA-1 Consortia
TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as Executive Director for its two newest public-private partnerships: the Critical Path for Lysosomal Diseases (CPLD) and the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortia . Klein brings a wealth of experience, having previously served as Executive Director of C-Path’s Transplant Therapeutics Consortium (TTC), where she orchestrated successful composite biomarker qualification submissions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency.Continue reading
World Parkinson’s Day Impact Story: C-Path’s Critical Path for Parkinson’s Consortium
Active Lifestyles Key for Parkinson’s Advocates Zenner-Dolan, Kwok as They Await Advancements in Treatments
By Alexander Diegel